Stockreport

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™ [Yahoo! Financ...

NKGen Biotech, Inc.  (NKGN) 
PDF 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function. Exploratory plasma GFAP correlations are consistent with ob [Read more]